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Abstract 
Our study aimed at finding a mechanistic relationship between the gut microbiome and 
breast cancer. Breast cancer cells are not in direct contact with these microbes, but disease 
could be influenced by bacterial metabolites including secondary bile acids that are 
exclusively synthesized by the microbiome and known to enter the human circulation. In 
murine and bench experiments, a secondary bile acid, lithocholic acid (LCA), reduced cancer 
cell proliferation (by 10-20%) and VEGF production (by 37%), aggressiveness and metastatic 
potential of primary tumors through inducing mesenchymal-to-epithelial transition, increased 
antitumor immune response, OXPHOS and the TCA cyle. Part of these effects was due to 
activation of TGR5 by LCA. Early stage breast cancer patients, versus control women, had 
reduced serum LCA levels, reduced chenodeoxycholic acid to LCA ratio, and reduced 
abundance of the baiH (7α/β-hydroxysteroid dehydroxylase, the key enzyme in LCA 
generation) gene in fecal DNA, all suggesting reduced microbial generation of LCA in early 
breast cancer. 
 
Keywords 
breast cancer, lithocholic acid, endothelial-mesenchymal transition, OXPHOS, microbiome, 
TGR5 
 
Highlights 
- Lithocholic acid (LCA), is a secondary bile acid produced only by bacteria. 
- LCA is cytostatic to breast cancer cells in vitro and in vivo in its serum reference 
range. 
- LCA treatment induces OXPHOS and the TCA cyle, inhibits EMT, VEGF expression 
and boosts antitumor immunity. 
- LCA expert its effects through the TGR5 receptor. 
- In early stage breast cancer patients bacterial LCA production is reduced. 
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1. Introduction 
The human body harbors a vast number of symbiotic, commensal and pathogenic 
bacteria in the bodily cavities and the body surface. The ensemble of these microbes is 
referred as the microbiota and its collective genome as the microbiome. Recent advances 
pointed out that changes in the composition of the microbiome and certain bacterial 
metabolites crucially impact metabolic, behavioral, cardiovascular and immune functions of 
the host and have pivotal roles in diseases that were previously not associated with bacteria 
[1-4]. Alterations of the microbiome are associated with certain cancers. Although, the 
microbiota may have a widespread role in carcinogenesis, the number of directly tumorigenic 
bacteria is extremely small, some 10 bacterial species fall into this category [5]. It seems 
more likely that pathological changes in the microbiota/microbiome (dysbiosis) determine 
susceptibility to the disease or influence the progression of the disease [4]. 
Most of these cancers affect those organs that are directly in contact with microbes such 
as the urinary tract [6], cervix [7], skin [8], airways [9], and the colon [4]. Such microbiome-
host interactions are best characterized in the colon. In the intestine a breach of the 
biological barrier between the microbes and the underlying tissues enables an adverse 
physical contact between microbes and host cells, that induces the production of paracrine 
bacterial metabolites [4]. Through these, the microbiome modulates tumorigenesis, tumor 
promotion, severity of the disease, and chemotherapy effectiveness in colonic tumors [4]. 
Direct stimulation of the cancer cells by bacteria probably has role in bacteria-mediated 
induction of lymphomas [10, 11] and possibly prostate cancer [6].  
Much less is known of the role of the microbiome in the regulation of those tumors that 
are located to different compartments and are indirectly connected to the microbiome 
through the circulation. Changes in the microbiome is associated with metabolic diseases 
(e.g. obesity or type II diabetes) [12]. These metabolic diseases are risk factors of certain 
cancers, among them, breast cancer [13, 14]. It is likely that similar mechanisms can confer 
susceptibility to cancer as to metabolic diseases. Blood-borne bacterial metabolites (e.g. 
short chain fatty acids) mediate human metabolism, hence these metabolites are likely 
candidates to be transported to a potential tumor by the bloodstream to exert carcinogenic or 
anti-carcinogenic effects in distant tumors. For hepatocellular carcinoma, lipopolysaccharide 
[15] and deoxycholic acid (DCA) [16] have been identified as promoters, while propionate, a 
short chain fatty acid (SCFA), is an inhibitor [17].  
Numerous bacterial metabolites have been identified that are either the microbes’ own 
metabolites (e.g., short chain fatty acids, lactate, pyruvate) or modified products of the host 
(e.g., secondary bile acids, metabolites of aromatic amino acids, redox-modified sex 
steroids) [18-20]. These bioactive metabolites act through various pathways that involve the 
modification of gene expression (e.g., activation of histone deacetylases and other lipid-
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mediated transcription factors) or the modulation of signal transduction in the host. Our aim 
with the current study was to investigate a potential causal link between changes in the 
microbiome, microbiome-derived metabolites and breast cancer. 
 
2. Materials and methods 
 
2.1. Chemicals 
All chemicals were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated. 
Radioactively labelled substrates for the pulse-chase metabolomics experiment were from 
Cambridge Isotope Laboratories, Andover, MA, USA. The inhibitors and antagonists used in 
the TGR5 experiments (U73343 (phospholipase C inhibitor), NF449 (Gsα-selective 
antagonist), CINPA1 (CAR antagonist), DY268 (FXR antagonist), GSK2033 (LXR 
antagonist)) were obtained from Tocris Bioscience and were used at the concentration of 5 
µM except for U73343 which was used at a final concentration of 1 µM.   
 
2.2. Image based correlation spectroscopy (ImFCS) 
After an exponential of polynomial bleach correction, pixel-by-pixel autocorrelation functions 
(ACFs) were calculated using a multi-tau correlation scheme [21]. To obtain the diffusion 
coefficient (D) for all pixels ACFs were fitted according to the equation in [21]. To identify and 
describe the mode of membrane organization by investigating the size-dependency of 
diffusion coefficient, we used the Imaging FCS type of FCS diffusion law [22]. According to 
that, the diffusion time (τ𝐷) of the fluorescent probe depends on the observation area (𝐴𝑒𝑓𝑓), 
as described by  
τ𝐷(𝐴𝑒𝑓𝑓) = τ0 +
𝐴𝑒𝑓𝑓
𝐷
 
where 𝐴𝑒𝑓𝑓 is the area of the membrane in which the labeled particle travels across,τ0 is the 
intercept of the diffusion law plot on the y-axis of 𝐴𝑒𝑓𝑓/D vs. 𝐴𝑒𝑓𝑓. This parameter provides 
information about the diffusion confinement. A more detailed description of the method can 
be found among the Supplementary Materials. 
 
2.3. Cell culture 
MCF7 cells were maintained in MEM (Sigma-Aldrich) medium supplemented with 10 % FBS, 
1 % penicillin/streptomycin and 2 mM L-glutamine at 37 °C with 5 % CO2. 
4T1 cells were maintained in RPMI-1640 (Sigma-Aldrich) medium containing 10 % FBS and 
1 % penicillin/streptomycin, 2 mM L-glutamine and 1 % pyruvate at 37 °C with 5 % CO2. 
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SKBR3 cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/l glucose) medium 
supplemented with 10 % FBS, 1 % penicillin/streptomycin and 2 mM L-glutamine at 37 °C 
with 5 % CO2. 
Primary fibroblasts cells were maintained in DMEM (Sigma-Aldrich, 1000 mg/l glucose) 
medium supplemeted with 20 % FBS, 1 % penicillin/streptomycin, 2 mM L-glutamine and 10 
mM HEPES at 37 °C with 5 % CO2.  
 
2.4. In vitro cell proliferation assays 
Sulphorhodamine B assays were described in [23]. For colony formation assays five hundred 
cells were seeded in a 6-well plate in complete medium and were cultured with the indicated 
concentrations of LCA for 7 days. At the end of the assay plates were washed twice in PBS. 
Colonies were fixed in methanol for 15 minutes, dried and stained according to May-
Grünwald-Giemsa for 15 minutes. Plate was washed with water and the colonies were 
counted using Image J software [24].  
 
2.5. Detection of cell death 
LCA-induced cytotoxicity was determined by propidium iodide (PI) uptake. Cells were seeded 
in 6-well plate (MCF7 - 200.000 cell/well; 4T1 - 75.000 cell/well) treated with LCA for two 
days and stained with 100 µg/ml propidium iodide for 30 min at 37 °C, washed once in PBS, 
and analyzed by flow cytometry (FACSCalibur, BD Biosciences). 
 
2.6. Scratch assay and video microscopy 
Cells were grown in 6-well plates until cell confluence reached about 70-80 %. The plates 
were manually scratched with sterile 200 µl pipette tip, followed by washing the cells twice 
with PBS. Then cells were incubated with vehicle or LCA (0.3 µM) in a thermostate. Cell 
densities were monitored every hour for one day using JuLi Br Live cell movie analyzer 
(NanoEnTek Inc., Seoul, Korea).  
 
2.7. Electric Cell-substrate Impedance Sensing (ECIS) 
ECIS (Electric cell-substrate impedance sensing) model Zθ, Applied BioPhysics Inc. (Troy, 
NY, USA) was used to monitor transcellular electric resistance of MCF7 and 4T1 cells 
seeded (MCF7- 40.000 cell/well; 4T1- 20.000 cell/well) on type 8W10E arrays. Cell were 
treated with vehicle or 0.3 µM LCA after 20 hours and total impedance values were 
measured for additional 48 hours. Multifrequency measurements were taken at 62.5, 125, 
250, 500, 1000, 2000, 4000, 8000, 16000, 32000, 64000 Hz. Modeling tool of ECIS was 
used to evaluate the Rb (barrier resistance) values of each of the wells at fix 180 s interval. 
The reference well was set to a no-cell control with complete medium.  
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2.8. DNA and mRNA preparation and quantitation; EMT screen 
DNA was extracted from fecal samples using PowerSoil DNA Isolation kit (MO BIO 
Laboratories, Inc. Carlsbad, California) according to the manufacturer’s instructions.  
Total RNA from cells and tumor samples were prepared using TRIzol reagent (Invitrogen 
Corporation, Carlsbad, CA).  
For the assessment of the expression of individual genes two micrograms of RNA were 
reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). The qPCR reactions were performed with qPCRBIO 
SyGreen Lo-ROX Supermix (PCR Biosystems Ltd, London, UK) on Light-Cycler 480 
Detection System (Roche Applied Science). Geometric mean of 36B4 and cyclophyllin was 
used for normalization. Primers are listed in Table 1. 
For the assessement of the abundance of the baiH ORF 10 ng of DNA (from fecal samples) 
was used for qPCR reactions. Primers are listed in Table 2. Specificity of the qPCR reactions 
were verified by sequencing PCR products with the primers used for the amplification. 
 
2.9. Metabolomics, pulse-chase metabolomics  
Cells, grown in the presence of LCA, were harvested after 48 hours of treatment. After 
quenching in liquid nitrogen the labelled (in D5030 medium for 1 hour were with 10 mM [U-
13C]-glucose or [2-13C]-acetate - Cambridge Isotope Laboratories, Andover, MA, USA) and 
unlabeled cells were extracted in methanol–chloroform–H2O solution at 4 °C. The 
supernatant was separated by centrifugation (15 000 g for 10 min at 4 °C) and stored at −80 
°C till further analysis. Drying and sonicating samples in 3-nitrobenzyl alcohol-trimethyl-
chlorosilane solution followed 80 °C incubation. The reaction was stopped by adding 
ammonium bicarbonate. The samples were diluted with acetonitril-water solution and the 
derivate metabolites were separated by reversed-phase chromatography in Waters Acquity 
LC system. For the measurements Waters Micromass Quattro Micro triple quadrupole mass 
spectrometer (Waters Corporation, Milford MA, USA) was operated with an electrospray 
source in positive ion mode. 
 
2.10. Measurement of oxygen consumption and extracellular acidification rate 
Oxygen consumption rate (OCR) and changes in pH, extracellular acidification rate (ECAR) 
were measured using an XF96 oxymeter (Seahorse Biosciences, North Billerica, MA, USA). 
Cells were seeded in 96-well Seahorse assay plate (MCF7 - 3000 cells/well; 4T1 - 1500 
cells/well) and treated with vehicle and LCA for two days. Then oxygen consumption was 
recorded every 30 minutes to follow the LCA effect. Data were normalized to protein content. 
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2.11. SDS-PAGE and Western blotting 
Cells were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS, 1 % TritonX 100, 0.5 
% sodium deoxycolate, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, protease 
inhibitor coctail). Protein extracts were separated on 10% SDS polyacrylamide gels and 
transferred onto nitrocellulose membranes by electroblotting. Membranes were blocked with 
5 % BSA, and incubated with primary antibodies for overnight at 4 °C. The membranes were 
washed with 1X TBS-TWEEN and probed with IgG HRP conjugated secondary antibodies 
(Cell Signaling Technology, Inc. Beverly, MA, 1:2000). Bands were visualized by enhanced 
chemiluminescence reaction (SuperSignal West Pico Solutions, Thermo Fisher Scientific Inc, 
Rockford, USA). Antibodies used in this study are listed in Table 3. 
 
2.12. Immunocytochemistry 
Cells were grown on coverslips, washed with PBS, fixed with 4 % paraformaldehyde for 15 
minutes and permeabilized using 1 % Triton X-100 for 5 minutes. Then cells were blocked 
with 1 % BSA for one hour and incubated with TexasRed-X Phalloidin (Invitrogen, Oregon, 
USA) for 45 minutes for the analysis of cellular morphology. Typical mesenchymal-like 
morphology and epithelial-like morphology of MCF7 and 4T1 cells are represented on Fig. 
S3. 
For cellular localization of NRF1 protein cells were incubated overnight with NRF1 primary 
antibody at 4 °C.  After washing steps, cells were incubated with secondary antibody (1:600, 
anti-rabbit Alexa 488, Life technologies) for 1 hour at room temperature. Cell nuclei were 
visualized with TO-PRO-3 iodide (1:1000, Life technologies). Coverslips were rinsed and 
mounted in Mowiol/Dabco solution. Confocal images were acquired with Leica SP8 confocal 
microscope and LAS AF v3.1.3 software. 
 
2.13. Transfections 
Silencer Select siRNA targeting TGR5 (GPBAR1- cat.no. 4392420; siRNA ID: s195791), 
VDR cat.no. 4390824; siRNA ID: s14777) and Negative control siRNA #1 (cat.no. 4390843) 
were obtained from Thermo Fisher Scientific. Cells were seeded in 24-well plate (MCF7 - 
50.000 cell/well) and on next day cells were transfected with TGR5, VDR siRNA and 
negative control at a final concentration of 30 nM using Lipofectamine RNAiMAX transfection 
reagent (Invitrogen). Cells were incubated with transfection complexes in medium containing 
LCA (0.3 µM) for 48 h.  
 
2.14. Animal study 
All animal experiments were authorized by the local and national ethical board (reg. 
1/2015/DEMÁB) and were performed to conform the relevant EU and US guidelines. 
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Experimental animals were female BALB/c animals between 8-10 weeks of age (20-25 g). 
Mice were randomized for all experiments animals were. Animals were bred in the “specific 
pathogen free” zone of the Animal Facility at the University of Debrecen, and kept in the 
“minimal disease” disease zone during the experiment. Animal studies are reported in 
compliance with the ARRIVE guidelines. 
No more than six mice were housed in each cage (standard block shape 365 × 207 × 140 
mm, surface 530 cm2; 1284 L Eurostandard Type II. L from Techniplast) with Lignocel Select 
Fine (J. Rettenmaier und Söhne, Germany) as bedding. Mice had paper tubes to enrich their 
environment. Dark/light cycle was 12 h, and temperature 22 ± 1°C. Cages were changed 
once a week, on the same day. Mice had ad libitum access to food and water (sterilized tap 
water). The animal facility was overseen by a veterinarian. A total of 28 mice was used in this 
study, group sizes are indicated in the figure captions. 
 
2.14.1. 4T1 tumor injection 
4T1 cells were suspended (2x106/mL) in ice cold PBS-matrigel (1:1, Sigma-Aldrich) at 1:1 
ratio. From this suspension female BALB/c mice received 50 µL injections to their 2nd inguinal 
fat pads on both sides (105 cells/injection). Tumor growth and animal wellbeing was 
monitored daily. 
 
2.14.2. LCA treatment 
Animals received daily oral LCA treatments. LCA stock was prepared in 96% ethanol at 100x 
concentration (7.5 mM) for storage at -20°C. LCA stock was diluted each day to a working 
concentration of 75 µM in sterile PBS immediately before the treatment. Ethanol vehicle (1% 
in PBS) was prepared and diluted similarly. Animals received a daily oral dose of 200 µL/30 g 
bodyweight from the LCA solution or the vehicle. Researchers administering LCA and vehicle 
solutions were blinded. Treatment was administered every day at the same time during the 
morning hours between 8am and 10am.   
 
2.14.3. Infiltration score 
During autopsy tumors were visually assessed and scored based on their infiltration rate into 
surrounding tissues. If the tumor mass remained in the mammary fat pads without any 
detectable attachment to muscle tissues then it was classified as a “low infiltration” tumor. In 
case the tumor mass attached to the muscle tissue below the fat pad but hasn’t penetrated it 
then it was classified as a “medium infiltration” tumor. Finally, if the tumor mass grew into the 
muscle tissue and penetrated the abdominal wall then it was scored a “high infiltration” 
tumor. Researchers involved in scoring primary tumors for their infiltration rate were blinded. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
2.14.4. TIL calculation 
Tumor infiltrating lymphocytes (TIL) content of tumors was expressed as the number of TILs 
per 100 tumor cells. 
 
2.15. Human studies 
The study in which human feces samples were collected from healthy subjects and breast 
cancer patients was developed by collaborators at the National Cancer Institute (NCI), Kaiser 
Permanente Colorado (KPCO), the Institute for Genome Sciences at the University of 
Maryland School of Medicine, and RTI International. The study protocol and all study 
materials were approved by the Institutional Review Boards at KPCO, NCI, and RTI 
International (IRB number 11CN235). 
The study in which human serum samples were collected from healthy subjects and breast 
cancer patients was developed by collaborators at the University of Debrecen (Hungary). 
The study protocol and all study materials were approved by the Institutional and Hungarian 
Review Boards (3140-2010).  
Cohort for fecal DNA and serum studies are listed in Table 4. 
 
2.15.1. Serum bile acid determination 
Serum bile acid profile was assessed as in [25]. 
 
2.16. Database search 
The kmplot.com database was used to study the link between gene expression levels and 
breast cancer survival in humans. The association of known mutations with breast cancer 
was retrieved from www.intogen.org/. Gene expression profiles were retrieved from the Gene 
expression omnibus (www.ncbi.nlm.nih.gov/geoprofiles/). The sequence of the baiH ORF or 
the bai operon was retrieved from the KEGG (www.genome.jp/kegg/) and the PATRIC 
databases (www.patricbrc.org/). 
 
2.17. Statistical analysis 
We used two tailed Student’s t-test for the comparison of two groups unless stated 
otherwise. Fold data were log2 transformed to achieve normal distribution. For multiple 
comparisons one-way analysis of variance test (ANOVA) was used followed by Tukey’s 
honestly significance (HSD) post-hoc test. Data is presented as average ± SD unless stated 
otherwise, percent changes are listed in Table 5. Outliers were identified for Fig. S3B using 
the Thomson tau-test. Statistical analysis was done using GraphPad Prism VI software.  
 
3. Results 
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3.1. Lithocholic acid attenuates the aggressiveness of experimental breast cancer 
Primary bile acids are converted to secondary bile acids exclusively by the intestinal 
microbiota [26]. Therefore, changes elicited by secondary bile acids directly implicate the 
involvement of the intestinal microbiota. We investigated three secondary bile acids, 
lithocholic acid (LCA), deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in 
concentrations corresponding to their normal (reference) concentrations in human serum and 
breast tissue (10 nM – 10 μM) [19, 27] first in short term proliferation assays. LCA reduced 
cellular proliferation of MCF7, SKBR3 and 4T1 breast cancer cells but did not affect primary 
fibroblasts (10 nM – 10 μM) (Fig. 1A, Table 5). Other secondary bile acids such as DCA or 
UDCA were without effect on MCF7 and 4T1 breast cancer cells (Fig. 1B). In the subsequent 
assays we used LCA concentrations higher than the reference serum concentration of LCA 
(~30-50 μM) as higher LCA concentrations (100-1000 nM) were reported in the breast [27]. 
The cytostatic effect of LCA was verified in longer colony forming assays (Fig. 1C, Table 5). 
The percent of propidium-iodide positive cells did not change upon LCA treatment 
suggesting that LCA did not induce cell death (Fig. 1D).  
We tested the cytostatic property of LCA in mice that were grafted with 4T1 cells and 
were treated with LCA (15 nmol LCA p.o. q.d.) or vehicle for 18 days. At the time of the 
sacrifice the infiltration capacity of the primary tumor to the surrounding tissues markedly 
decreased upon LCA treatment (Fig. 2A). Furthermore, the number of the metastases was 
also lower in the LCA-treated group (Fig. 2B). 
 
3.2. LCA interferes with multiple anticancer molecular pathways 
After finding the cytostatic property of LCA in breast cancer, we investigated how LCA 
modulates the different features of breast cancer through assessing classical hallmarks of 
cancer [28]. 
LCA inhibited tumor infiltration and metastasis formation (Fig. 2A-B), implicating 
modulation of the epithelial-mesenchymal transition (EMT) and cellular movement. LCA 
treatment improved cell-to-cell connections, an epithelial feature, as reflected by epithelial-
like morphology in cells (Fig. 3A, Fig. S3A) and improved total impedance (Fig. 3B, Table 5) 
that provide functional evidence of better cell-to-surface and cell-to-cell adhesion. LCA-
treatment inhibited β-catenin signaling as evidenced by lower GSK-3α and GSK-3β 
phosphorylation and lower β-catenin protein content both in cell lines and in vivo (Fig. 3C, 
Fig. S3B). Furthermore, LCA-treated 4T1 cells were slower in moving into a void area in a 
scratch assay as compared to vehicle-treated ones (Fig. 3D). In addition, we found lower 
VEGF mRNA expression (Fig. 3E, Table 5) and higher number of tumor infiltrating 
lymphocytes (TILs) in LCA-treated as compared to vehicle-treated ones mice (TILs) (Fig. 
3F).  
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Breast cancer depends on Warburg metabolism [29]. Therefore, we assessed LCA-
induced changes in cellular metabolism. LCA treatment induced glycolysis (extracellular 
acidification rate - ECAR) and mitochondrial respiration (oxygen consumption rate - OCR) 
levels (Fig. 4A). In line with that, intracellular lactate and citrate levels, as well as, 
citrate/lactate ratio increased upon LCA treatment (Fig. 4B). In line with these observations, 
LCA-induced the expression of a set of OXPHOS genes in 4T1 and MCF7 cells (Fig. 4C, 
Table 5). 
Next, we performed pulse-chase metabolomics experiments in MCF7 and 4T1 cells 
treated with 300 nM LCA. When cells were charged with 13C-acetate, a metabolite that can 
fuel the TCA cycle, LCA treatment enhanced the incorporation of 13C into succinate and 
malate (Fig. 4D) suggesting increased flux through the TCA cycle. Next, we fed cells with 
13C-glucose from which 13C atoms must enter glycolysis to subsequently feed the TCA cycle 
or form lactate. LCA treatment enhanced the amount of 13C-labelled citrate and lactate in 
MCF7 cells and the amount of 13C-labelled succinate and lactate in 4T1 cells (Fig. 4E). In 
line with these observations, the ratio between 13C-citrate and 13C-lactate or between 13C-
succinate and 13C-lactate increased, providing further evidence towards mitochondrial 
dominance of the LCA-induced metabolic switch (Fig. 4E). We assessed the distribution of 
13C-labelled carbons in citrate in vehicle and LCA-treated MCF7 cells. More carbons were 
13C-labelled in citrate in the LCA-treated cells as compared to vehicle treated ones (Fig. S4) 
suggesting a more rapid turning of the TCA cycle. Taken together, LCA treatment induced 
the TCA cycle and oxidative phosphorylation (OXPHOS) in breast cancer cells. 
We assessed components of the cellular energy sensor web and mitochondrial 
transcriptional regulators to find the roots of the above metabolic changes. LCA-induced 
expression and activation of positive regulators of mitochondrial oxidative phosphorylation 
FOXO1, PGC-1β and nuclear respiratory factor-1 (NRF1) (Fig. 5A, Fig S5A). LCA not only 
boosted their expression but also enhanced their activation that is evidenced by enhanced 
nuclear translocation of NRF1 and the higher phosphorylation of ACC (Fig. 5A, B, Fig S5A, 
C). In the in vivo experiments we also observed the LCA-mediated induction of AMPK activity 
(marked by increased phospho-ACC and phospho-AMPK levels) and enhanced expression 
of FOXO1 as well, although neither NRF1, nor PGC-1β expression was induced by LCA 
(Fig. 5C, Fig S5B). 
Subsequently, we assessed whether the induction of the metabolic regulators (NRF1, 
AMPK, PGCs) have (patho)physiological relevance in humans. Previous studies have 
underlined the antitumor activity of AMPK and FOXO1 in humans [23, 30, 31]. Using the 
kmplot.com database we found that high expression of NRF1 in breast cancer tissue is 
predictive of better survival post-diagnosis (Fig. 5D). Although no frequent (driver) mutations 
were found in PGC-1β according to the Intogen database, it did appear that the expression of 
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PGC-1β was reduced in tumor as compared to healthy tissues [32, 33] and in metastases as 
compared to the primary tumors [34]. Taken together, the modulation of AMPK, FOXO1, 
PGC-1β or NRF1 may have (patho)physiological relevance in modulating LCA-evoked 
effects in humans.  
Next, we aimed to identify the LCA receptor(s) responsible for the above effects. We 
used pharmacological inhibitors designed to inhibit different LCA receptors (see Materials 
and methods) to test their involvement in the LCA-induced effects. MCF7 cells were treated 
with LCA together with vehicle or pharmacological agents blocking the potential LCA 
receptors. LCA-mediated reduction in cell proliferation was efficiently blocked by CINPA1, 
NF449 and U73343; other inhibitors were ineffective (Fig. 6A, Table 5). NF449 and U73343, 
unlike CINPA1, efficiently blocked LCA-induced morphological changes (closure of the void 
areas among cells, epithelial-like morphology) in MCF7 and 4T1 cells (Fig. 6B). Since NF449 
and U73343 are not TGR5-specific inhibitors but block TGR5 signaling, by inhibiting Gsα and 
phospholipase C, we transiently silenced TGR5 in MCF7 cells (Fig. 6C, D, Fig. S6A, Table 
5) to provide direct evidence for the involvement of TGR5. Silencing of TGR5 efficiently 
blocked LCA-induced morphological changes (Fig. 6E) and blocked the LCA-induced 
increases in the mRNA expression of CYTOCHROME C, ATP5G1 and NDUFB5 
mitochondrial markers (Fig 6F, Table 5) and markers of AMPK activation (Fig. 6G, Fig. 
S6B). Silencing of VDR receptor had no effect on LCA- induced changes (data not shown). It 
is also of note that LCA, in the concentrations used in this study, enters biomembranes but 
does not alter either its dynamical properties or microdomain organization, since neither the 
diffusion constant (D), nor the confinement time (ƬD) changed even upon 100 μM LCA 
treatment (Fig. 6H). 
 
3.3. LCA biosynthesis is suppressed in early phases of human breast cancer 
We next investigated how bile acid and LCA metabolism relates to breast cancer in 
humans. LCA is produced through deconjugation of chenodeoxycholic acid (CDCA) 
conjugates, followed by a dehydroxylation on carbon 7 by the action of the enzyme 7α/β 
hydroxysteroid dehydrogenase (7-HSDH) [26] that is the rate-limiting step of LCA formation. 
The enzymes involved in the 7-dehydroxylation of bile acids are organized into one operon 
called the bile acid-inducible (bai) operon wherein the baiH ORF codes for 7-HSDH in most 
bacterial species [26]. 
baiH abundance was assessed by amplifying baiH ORF from fecal DNA using specific 
primers. To validate this mode of measurement, we treated mice with ciprofloxacin (CPX), an 
antibiotic that specifically kills aerobic bacteria, while leaving the anaerobic bacteria intact. 
When mice were treated with CPX (200 mg/kg q.d. for two weeks) the abundance of 
staphylococcal, escherichial and pseudomonal baiH (aerobic bacteria) decreased, while the 
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ratio of the baiH of the anaerobic bacteria (Bacteroides fragilis, Clostridium scindens) did not 
change (Fig. 7), as expected from the biology of the antibiotic that supports this approach. 
Total bile acid, CDCA and LCA levels were reduced in serum from breast cancer 
patients as compared to age and sex matched healthy individuals (Fig. 8A, B, C, Table 6), 
and we observed a similar trend in all other bile acids we examined (Fig. 8A, Table 6). Since 
both primary and secondary bile acid levels were lower in breast cancer patients, we 
assessed the ratio between CDCA (the substrate for LCA synthesis) and LCA in human 
serum. We found a decrease in the LCA/CDCA ratio in breast cancer patients compared to 
healthy individuals, and this decrease that was more marked when only stage 1 patients 
were assessed (Fig. 8D). At later stages LCA/CDCA ratio normalized and even increased 
above the ratio of healthy individuals in stage 3 patients. These data are in good correlation 
with the data of Tang an co-workers [35] demonstrating that glycolithocholate sulphate levels 
were lower in breast cancer patients compared to controls (additional file 3, line 239). 
To get an insight how intestinal LCA biosynthesis is altered in breast cancer patients, we 
assessed the abundance of the baiH ORF in human fecal DNA from the experimental cohort 
described in [36] (Table 4, cohort 2). In order to do that we searched for bacterial species 
where the ORF for baiH was annotated. We identified the baiH ORF of anaerobic, Gram 
positive and Gram negative species and measured the abundance of the baiH DNA in fecal 
DNA samples using qPCR assays. When all patients were compared to healthy controls the 
abundance of baiH of Clostridium sordelli, Staphylococcus haemolyticus, Escherichia coli 
and Pseudomonas putida was lower in breast cancer patients (Fig. 8E) in line with the lower 
LCA levels and LCA/CDCA ratio. A more pronounced decrease in the abundance of the baiH 
of Bacteroides thetaiotaomicron, Clostridium sordelli, Staphylococcus haemolyticus, 
Escherichia coli and Pseudomonas putida were observed in stage 0 and stage 1 patients 
than in the pool of all patients (Fig. 8F). 
Taken together, the bacterial LCA biosynthesis machinery in the intestine is 
downregulated in breast cancer patients that is very pronounced in the early phase of the 
disease. Lower capacity to synthesize LCA then contributes to lower LCA levels. These 
findings together with the observation of Tang and co-workers [35] that glycolithocholate 
sulphate levels have a significant negative correlation with Ki67 positivity (additional file 9, 
line 110) in human breast cancer tumors, pointing towards the involvement of bacterial LCA 
metabolism in human breast cancer pathogenesis. 
 
4. Discussion 
This study nominates LCA, a metabolite of the microbiota, to be synthesized in the gut 
and thereafter transferred through the bloodstream to the breast where it may be an 
important player in bringing about an anti-cancer tumor microenvironment. In our studies 
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LCA inhibited the proliferation of breast cancer cells, while it did not interfere with primary 
cells. In previous studies [37, 38] LCA induced cell death in neuroblastoma, prostate cancer, 
and MCF7 cells. However, the LCA concentrations utilized in those studies [37, 38] were 
higher than the one used in our present study, which may explain why we did not observe 
acute LCA toxicity. As we noted earlier, 100-1000 nM LCA concentration, used in this study, 
stands closer to the LCA concentrations reported in the breast [27]. 
To date no direct, causal relationship had been shown between the microbiome and 
breast cancer, although studies have suggested an interconnection. Specifically, the gut 
microbiome had been suggested to facilitate breast cancer progression through 
deconjugating estrogens making them more prone for reuptake [36, 39]. Goedert and co-
workers [36] have assessed microbiome changes in breast cancer patients, finding that 
postmenopausal breast cancer patients had reduced diversity and altered composition of the 
gut microbiome compared to closely matched control women. In addition, bacteria were 
identified on breast duct surfaces, and differences in the microbiome of breast cancer tissue 
has also been observed [14, 40-42]. These findings suggest that LCA may be produced by 
the breast’s own microbiota and not only by the gut microbiome. However, the share of the 
two sources (breast vs. gut) in LCA production is not known.  
A causative relationship between the microbiome and breast cancer is further 
strengthened by the suggestive association between antibiotic treatment and incidence or 
recurrence of breast cancer [43-48]. Although the chance of uncontrolled confounding is high 
and some studies have found no association, evidence for a dose-response relationship 
between antibiotic exposures and breast cancer incidence has been found [43, 44, 46-48]. 
The correlation between antibiotic use and breast cancer incidence was also found in males 
[48]. The cancer association has not been tied to a particular antibiotic class, but the 
strongest correlations have been with tetracyclins and macrolids [45]. These observations 
support our hypothesis on the relationship between microbiota functions and breast cancer. 
Which bacterial species are important in LCA-mediated modulation of breast cancer? 
This question is hard to answer at the moment. Goedert and colleagues [36] found that in the 
gut microbiota breast cancer cases had increased relative abundance of Clostridiaceae, 
Faecalibacterium, and Ruminococcaceae and decreased Dorea and Lachnospiraceae taxa. 
In contrast to that, previous studies showed that anaerobic microbes are instrumental in the 
production of secondary bile acids, such as LCA [26]. In our study, hereby, we demonstrated 
decreases in both the aerobic and the anaerobic microbial populations with early stage 
breast cancer suggesting widespread suppression of the microflora in breast cancer that 
culminates in decreased LCA production. These imply the contribution of the aerobic flora in 
LCA synthesis. 
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Hereby, we demonstrate the antiproliferative effects of LCA against breast cancer cells. 
In contrast to that, previous studies have pointed out possible oncogenic properties to 
secondary bile acid [20]. LCA was shown to possess transforming capacity towards colon 
epithelial cells [20], while DCA, that is inactive in our model systems, was shown to 
reprogram hepatocyte secretome and through that promote hepatocellular carcinoma [16, 
49]. Bile acids also are implicated in pharyngeal cancer [50]. The explanation for these 
differences are yet unknown. 
To our best knowledge, this is the first study that provides mechanistic evidence of 
crosstalk between the microbiome and breast cancer by describing LCA as a bacterial 
metabolite with antiproliferative effects in breast cancer. It is very likely that other bacterial 
metabolites that can increase or, like LCA, inhibit the proliferation of breast cancer cells will 
be described in the future. The fact that the composition of the microbiome influences breast 
cancer may provide novel approaches to cancer risk estimation and prevention. 
 
5. Conclusions 
In this study we show that a bacterial metabolite, lithocholic acid, can limit the proliferation of 
breast cancer cells in vitro and in vivo through activating TGR5 receptor, furthermore, in early 
stages of breast cancer LCA biosynthesis and LCA levels drop suggesting a role for this 
pathway in human disease. 
 
List of abbreviations 
ACC - Acetyl-CoA Carboxylase 
AMPK - AMP -Activate Kinase 
ATP5g1 - ATP Synthase, H+Transporting, Mitochondrial Fo Complex Subunit C1 (Subunit 9) 
bai operon - bile acid-inducible operon 
CDCA - chenodeoxycholic acid  
CPX - ciprofloxacin 
CYTC - Cytochrome C, Somatic (CYCS) 
DCA - deoxycholic acid  
ECAR - extracellular acidification rate  
ECIS - Electric Cell-substrate Impedance Sensing 
EMT - epithelial-mesenchymal transition 
FOXO1 - Forkhead Box O1  
LCA - lithocholic acid 
ImFCS - Image based correlation spectroscopy 
NDUFB5 - NADH Dehydrogenase (Ubiquinone) 1 Beta Subcomplex, 5 
NRF1 - Nuclear Respiratory Factor-1 
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OCR - oxygen consumption rate 
OXPHOS – Oxidative phosphorylation 
PGC-1β - Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Beta 
PI - propidium iodide  
SRB assay - Sulphorhodamine B assay 
TGR5/GPBAR1 - G Protein-Coupled Bile Acid Receptor 1 
TIL - tumor infiltrating lymphocytes 
UDCA - ursodeoxycholic acid  
VEGFA - Vascular Endothelial Growth Factor A 
7-HSDH - 7α/β hydroxysteroid dehydrogenase 
 
Data availability 
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https://figshare.com/s/66407d07fe82b289c1bd. The dataset will become freely available 
upon the acceptance of the manuscript. 
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Figure legends 
Figure 1. LCA inhibits the proliferation of breast cancer cells  
(A) MCF7, 4T1, SKBR3 cells and primary fibroblasts were treated with LCA in the 
concentrations indicated for 48 hours then total protein concentration was determined in SRB 
assays (MCF7: n=8; 4T1: n=6; SKBR3: n=3; fibroblasts n=5). Values expressed as fold 
changes, where 1 means protein content in the control cells and is marked by a dotted line. 
(B) MCF7 and 4T1 cells were treated with DCA or UDCA in the concentrations indicated for 
48 hours then total protein concentration was determined in SRB assays (MCF7: n=4; 4T1: 
n=3). (C) MCF7 and 4T1 cells were treated with LCA in the concentrations indicated for 7 
days and colonies were stained according to May-Grünwald-Giemsa that were then counted 
using the Image J software (MCF7: n=3, 4T1: n=4). (D) MCF7 and 4T1 cells were treated 
with LCA in the concentrations indicated for 48 hours. Dead cells were stained by propidium 
iodide (PI) and analyzed by flow cytometry (MCF7, 4T1: n=3). 
* and ** indicate statistically significant difference between vehicle and treated groups at 
p<0.05 or p<0.01, respectively.  
 
Figure 2. LCA supplementation reduces cancer aggressiveness in vivo 
(A-B) Female Balb/c mice were grafted with 4T1 cells as described and were treated with 
LCA (15 nmol q.d. p.o.) or vehicle (VEH) (n=8/8) for 18 days before sacrifice. Upon autopsy 
(A) tumor infiltration was scored and (B) the number of metastases were determined. 
On panel A significance was calculated using the Freeman-Halton extension of the Fisher 
exact probability test for a 2x3 contingency table. * indicate statistically significant difference 
between vehicle and treated groups at p<0.05. Error is shown as SEM. 
 
Figure 3. LCA treatment reverses EMT and improves antitumor immune response 
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A part of the experiments were performed on MCF7 and 4T1 cells treated with LCA in the 
concentrations indicated for 48 hours, or on female Balb/c mice grafted with 4T1 cells that 
were treated with LCA (15 nmol q.d. p.o.) or vehicle (VEH) (n=8/8) for 18 days. 
(A-B) In LCA or VEH-treated MCF7 and 4T1 cells (A) cellular morphology was assessed 
after Texas Red-X Phallodin- and To-Pro-3 staining (representative figure, n=3), (B) total 
resistance was measured in ECIS experiments (mean ± SD, n=3). (C) In LCA-treated 4T1 
and MCF7 cells, as well as in tumor samples the expression of the indicated proteins were 
analyzed by Western blotting (MCF7, 4T1 n=3, representative figures throughout). (D) 
Scratch assays were performed on 4T1 cells (n=3). (E) VEGF expression was determined in 
tumors using RT-qPCR (mean marked by a line). (F) The morphology in LCA or VEH-treated 
tumors were assessed in hematoxilin-eosine stained 4 µm thick histological sections and the 
number of tumor infiltrating lymphocytes (mean marked by a line) was counted in the 
sections. The relative numbers of TILs were determined according to the recent diagnostic 
procedure by counting both the tumor cells and the intratumor lymphocytes within the same 
representative areas of the HE stained slides. TIL counts were given in relation to tumor cell 
count in percentage. Stars mark typical tumor cells, TILs are marked by arrows.  Scale bar 
on panel (A) is 10 µm and 50 µm on panel (F). 
*, ** and *** indicate statistically significant difference between vehicle and treated groups at 
p<0.05, p<0.01 or p<0.001 respectively. Abbreviations are in the text. 
 
Figure 4. LCA treatment induces the TCA cycle and OXPHOS in breast cancer cells 
(A-E) MCF7 and 4T1 cells were treated with LCA in the concentrations indicated for 48 hours 
then the indicated measurements were performed. (A) Extracellular acidification rate (ECAR) 
(average± SD of a representative measurement, n=2) and oxygen consumption rate (OCR) 
(average±SD of a representative measurement, n=2) were performed and data were plotted. 
(B) Intracellular lactate levels (MCF7, 4T1: n=2) and citrate levels were determined (MCF7, 
4T1: n=2) and were plotted. (C) The expression of a set of genes were determined in RT-
qPCR reactions (MCF7 n=3, 4T1 n=2; error is depicted as SEM). (D) MCF7 and 4T1 cells 
were treated with LCA in the concentrations indicated for 48 hours then cells were loaded 
with 10 mM 13C-acetate for 1 hour that was followed by the determination of the indicated 
metabolites. (E) MCF7 and 4T1 cells were treated with LCA in the concentrations indicated 
for 48 hours then cells were loaded with 10 mM 13C-glucose for 1 hour that was followed by 
the determination of the indicated metabolites.  
* indicate statistically significant difference between citrate or OCR values of vehicle and 
treated groups at p<0.05. # or ## indicate statistically significant difference between lactate 
or ECAR values of vehicle and treated groups at p<0.05 or p<0.01, respectively.     
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
21 
 
Figure 5. LCA treatment induces elements of the energy stress sensors 
(A) MCF7 and 4T1 cells were treated with LCA in the concentrations indicated for 48 hours 
then protein extracts were separated by PAGE, blotted onto nitrocellulose and probed with 
the antibodies indicated. (MCF7, 4T1: n=3) (B) NRF1 localization was assessed by 
immunofluorescence and image analysis. Scale bar equals to 50 µm. (C) Female Balb/c 
mice were grafted with 4T1 cells were treated with LCA (15 nmol q.d. p.o.) or vehicle (VEH) 
for 18 days. Protein, extracted from the primary tumors, was separated by PAGE, blotted 
onto nitrocellulose and probed with the antibodies indicated. (D) The impact of NRF1 
expression on survival in breast cancer was evaluated by assessing the kmplot.com 
database. 
Abbreviations are in the text. ** and *** indicate statistically significant difference between 
vehicle and treated groups at p<0.01 or p<0.001, respectively. 
 
Figure 6. LCA-evoked anticancer effects are partly mediated by TGR5 
(A) MCF7 cells were treated with 0.3 μM LCA and the agents as follows: 5 μM NF449, 1 μM 
U73343, 5 μM CINPA1, 5 μM DY268 and 5 μM GSK2033 for 48 hours, then cellular 
proliferation was determined (n=3). (B) MCF7 and 4T1 cells (n=3) were treated with 0.3 μM 
LCA and the agents as follows: 5 μM NF449, 1 μM U73343 and 5 μM CINPA1 for 48 hours, 
then actin was stained with Texas-Red-X-phalloidin. Arrows point at void areas around cells 
and lost focal adhesion sites. Scale bar equals to 25 µm. (C-D) TGR5 was silenced in MCF7 
cells by transiently transfecting an siRNA or a negative control, non-specific siRNA to the 
cells for 48 hours, then (C) mRNA and (D) protein expression of TGR5 was determined. (E-
G) TGR5 depleted and negative control-transfected MCF7 cells were treated with 0.3 μM 
LCA for 48 hours. (E) Cells were stained with Texas-Red-X-phalloidin. Arrows point at void 
areas around cells and lost focal adhesion sites. Scale bar equals to 25 µm. The (F) mRNA 
expression of the indicated genes were determined by RT-qPCR, while (G) the expression 
levels of the indicated proteins were determined by Western blotting.  
(H) Supported bilayer with ternary lipid composition of DOPC/SM/cholesterol in 1/1/1 ratio 
was treated with 100 µM LCA for 20 minutes. Diffusion coefficients of STAR 488 PEG-
cholesterol probe in control and treated membranes. Confinement times of the probe in 
control and treated membranes. Error bars represent the standard deviations (n=6). Please 
note that the LCA concentration was 33 times higher than the highest concentration applied 
in in vivo or in vitro experiments. 
* and ** indicate statistically significant difference between vehicle and treated groups at 
p<0.05 or p<0.01 respectively.     
 
Figure 7. Ciprofloxacin treatment alters the abundance of baiH DNA 
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Balb/c female mice were grafted with 106 4T1 cells. Feces was collected before grafting and 
18 days post grafting. Fecal DNA was isolated and the abundance of the baiH ORF of the 
bacterial species indicated on the figure was assessed in these samples in qPCR reactions. 
Abbreviations are in the text. ** indicates statistically significant difference between vehicle 
and treated groups at p<0.01. 
 
Figure 8. In early stages of human breast cancer bacterial LCA biosynthesis is 
suppressed 
(A-D) Serum samples from the healthy controls and breast cancer patients of cohort 1 were 
pooled. (A) The bile acid composition of these pooled samples were determined. (B) By 
summing the different bile acid species total serum bile acid content was calculated. (C) 
Serum CDCA and LCA levels from the samples of healthy controls and breast cancer 
patients are plotted. (D) LCA/CDCA ratio was calculated from the samples of healthy controls 
and breast cancer patients. (E-F) The abundance of the baiH DNA was determined in the 
fecal DNA samples of cohort 2 (median values indicated by a line). Values where ct was 
lower than 45 were removed. Panel E depicts only the comparison of the control vs. cases, 
therefore, on that panel Student’s t-test was used to determine statistical significance. 
* and ** indicate statistically significant difference at p<0.05 and p<0.01 between the groups 
indicated, respectively. 
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Table 1. Primers used in the RT-qPCR reactions 
Gene Symbol Murine forward and reverse primer (5’-
3’) 
Human forward and reverse primer (5’-3’) 
Atp5g1 GCTGCTTGAGAGATGGGTTC  
AGTTGGTGTGGCTGGATCA 
CTAAACAGCCTTCCTACAGCAACTT 
TGAACCAGCCACACCAACTGT 
Ndufb5 CTTCGAACTTCCTGCTCCTT 
GGCCCTGAAAAGAACTACG 
GTATTCATTGGTCAAGCTGAACTAG 
CAGCTCCTTTACCCGTAATTCAGC 
Cytc TCCATCAGGGTATCCTCTCC 
GGAGGCAAGCATAAGACTGG 
TAAGAACAAAGGCATCATCTGG 
AGGCAGTGGCCAATTATTACTC 
36b4 AGATTCGGGATATGCTGTTGG 
AAAGCCTGGAAGAAGGAGGTC 
CCATTGAAATCCTGAGTGATGTG 
GTCGAACACCTGCTGGATGAC 
Cyclophilin TGGAGAGCACCAAGACAGACA 
TGCCGGAGTCGACAATGAT 
GTCTCCTTTGAGCTGTTTGCAGAC 
CTTGCCACCAGTGCCATTATG 
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Table 2. Primers used for the determination of baiH abundance using qPCR. 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
Bacteroides fragilis CGGGCAGATCGATGTACTGGT AGTACCATTCGAATCGGCCGT 
Bacteroides thetaiotaomicron CCCATCATGACCACTCACGGA AAGAACCAGTCCCGGTGCTAC 
Escherichia coli TATGGCGTTTGACCTGGGTGA CAAAGGAACAGCGCTGCGTTA 
Clostridium scindens GATGAGCTGGAGACCACCCTG GTAGCCGTAGTCTCGCTGTCA 
Clostridium sordelli TGCCATACTCCTGAAATCGAGT TCCCATCTTTCTTCAAATGTACGCT 
Staphylococcus haemolyticus CGTTTCTGTCGTGATAATGCCCT GGCGTGTTTGAATGGTCGCTT 
Pseudomonas putida GGGCGATGCACTGGACTTCTA ATGTGGGTGTTGTCCTCGAGG 
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Table 3. Antibodies used in the study 
antibody/die concentration vendor 
Phospho-ACC (Ser79) 1/1000 Cell Signaling Technology (#3661) 
Phospho-AMPKα (Thr172) 1/1000 Cell Signaling Technology(#2531) 
NRF1 1/1000 (WB) 
1/100 (immunocytochemistry) 
Abcam (ab175932) 
PGC1β 1/1000 Abcam (ab176328) 
FOXO1 1/1000  Cell Signaling Technology (#9454) 
Phospho-GSK-3α/β (Ser21/9) (D17D2) 1/2000 Cell Signaling Technology (#8566) 
GSK-3α/β (D75D3) 1/2000 Cell Signaling Technology (#5676) 
β-Catenin 1/1000 Sigma (C7082) 
TGR5/GPBAR1 1/1000 NOVUS (NBP2-23669) 
TexasRed-X Phalloidin 1/150 Life Technologies (T7471) 
ACTIN 1/20000 Sigma-Aldrich (A3854) 
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Table 4. Patient cohorts 
 
Cohort for serum studies- cohort 1 
 healthy patient of which 
stage 0 stage 1 stage 2 stage 3 stage 4 
number 56 56 - 16 25 10 5 
age (years) 59.1±7.3  60.7± 8 - 61.8 ± 5,5 61.5 ± 8,6 60.6 ± 8,2 53.8 ± 10 
sex female female female female female female female 
Patients were recruited at the Medical Center of the University of Debrecen. Patients were age and sex-matched with the staging was according 
to [51]. Patients with other cancers, inflammatory diseases, diseases affecting the GI tract and the liver or receiving antibiotics were excluded 
from the study. 
 
Cohort for fecal DNA studies – cohort 2 
 healthy patient of which Stage 
stage 0 stage 1 stage 2 stage 3 stage 4 
number 48 46 11 23 10 2 - 
sex female female female female female female - 
This cohort was published in [36]. Staging of the patients was performed according to [51].  
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Table 5. Primary data expressed as percent change for Fig 1A, 1C, 3C, 3E, 4C, 6A, 6B, 6C, 6F 
  LCA concentrations 
(µM) 
           
  CTL 0.1  0.3 1       
  AVG SD AVG SD AVG SD AVG SD       
Fig1A MCF7 100,00 0,00 83,52 8,95 85,81 5,57 85,68 8,87       
 4T1 100,00 0,00 91,88 6,67 92,25 3,99 92,24 5,16       
 SKBR 100,00 0,00 88,59 2,73 87,20 3,32 88,14 4,32       
                
  CTL 0.1  0.3 1       
  AVG SD AVG SD AVG SD AVG D       
Fig1
C 
MCF7 100,00 0,00 89,22 14,3
1 
75,72 3,40 80,75 1,65       
 4T1 100,00 0,00 74,15 18,0
4 
81,25 14,51 63,85 11,9
9 
      
                
  CTL LCA (0.3 µM)   
  0 24h 48h 0 24h 48h   
  AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD   
Fig3B MCF7 100,00 0,00 118,38 4,83 119,4
6 
10,16 100,0
0 
0,00 135,3
5 
2,00 129,4
4 
2,81   
 4T1 100,00 0,00 202,94 10,1
4 
287,5
3 
6,32 100,0
0 
0,00 238,7
5 
6,99 371,7
1 
16,8
2 
  
                
  CTL LCA           
  AVG SD AVG SD           
Fig3E in vivo/tumor 100,00 26,1
4 
63,91 28,5
8 
          
                
  LCA concentrations 
(µM) 
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  CTL 0.1  0.3 1       
  AVG SEM AVG SEM AVG SEM AVG SEM       
Fig4
C 
MCF7/CYTC 100,00 0,00 121,00 63,5
7 
201,0
0 
145,3
3 
191,6
7 
25,3
7 
      
 MCF7/ATP5G1 100,00 0,00 184,00 53,8
4 
308,5
0 
182,5
0 
143,6
7 
31,3
2 
      
 MCF7/NDUFB
5 
100,00 0,00 168,33 32,9
4 
225,2
5 
61,17 151,7
5 
13,0
4 
      
 4T1/CYTC 100,00 0,00 93,00 4,51 209,3
3 
95,25 95,00 2,00       
 4T1/ATP5G1 100,00 0,00 119,00 26,0
0 
138,0
0 
7,00 109,0
0 
21,0
0 
      
 4T1/NDUFB5 100,00 0,00 120,67 14,2
4 
211,6
7 
32,67 127,3
3 
26,0
3 
      
                
  CTL LCA  NF449+LCA U73343+LCA CINPA1+LCA DY268+LCA GSK2033+LC
A 
  AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD AVG SD 
Fig6A MCF7 100,00 0,00 75,99 9,95 97,44 11,18 83,69 10,1
5 
88,83 12,9
2 
63,86 10,8
8 
72,75 9,74 
                
  siNEG  siTGR5            
  AVG SD AVG SD           
Fig6
C 
MCF7 100,00 0,00 42,06 14,8
6 
          
                
  CTL  siNEG+LCA siTGR5+LCA         
  AVG SD AVG SD AVG SD         
Fig6F MCF7/CYTC 100,00 0,00 200,96 9,11 144,4
9 
44,62         
 MCF7/ATP5G1 100,00 0,00 178,93 8,26 112,1
8 
53,39         
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 MCF7/NDUFB
5 
100,00 0,00 121,49 7,58 104,1
1 
30,04         
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Table 6. Bile acid composition of the human serum samples (compare to Fig. 5 A-D) 
 
Primary bile acids (µmol/L) 
 
CA GCA TCA CDCA GCDCA TCDCA 
Control 0,287 0,301 0,071 0,563 0,931 0,137 
Breast cancer 0,116 0,166 0,033 0,262 0,761 0,173 
  Stage 1 0,170 0,126 0,020 0,342 0,591 0,078 
  Stage 2 0,092 0,177 0,043 0,198 0,874 0,263 
  Stage 3 0,113 0,170 0,033 0,205 0,710 0,150 
 
Secondary bile acids (µmol/L) 
 
DCA GDCA TDCA LCA GLCA UDCA GUDCA 
Control 0,701 0,415 0,061 0,031 0,025 0,147 0,330 
Breast cancer 0,384 0,304 0,045 0,017 0,023 0,069 0,209 
  Stage 1 0,385 0,261 0,038 0,016 0,014 0,114 0,233 
  Stage 2 0,377 0,345 0,049 0,018 0,029 0,058 0,209 
  Stage 3 0,323 0,297 0,043 0,020 0,026 0,027 0,157 
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